Slow controlled released combsn. preparation of semisolid framework of containing glipizide

A technology of glipizide and semi-solid, which is applied in the field of sustained and controlled release semi-solid matrix preparation compositions, and can solve the problems of high incidence of toxic and side effects, frequent administration, and inability to release drugs stably for a long time

Inactive Publication Date: 2005-11-16
SHANGHAI INST OF PHARMA IND CO LTD
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The technical problem to be solved in the present invention is to disclose a slow and controlled release semi-solid matrix preparation composition containing glipizide, so as to overcome the problems in the prior art that the drug cannot be released stably for a long time in the body, the number of administrations is high, and the side effects High-incidence conditions to improve patient safety and compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Slow controlled released combsn. preparation of semisolid framework of containing glipizide
  • Slow controlled released combsn. preparation of semisolid framework of containing glipizide
  • Slow controlled released combsn. preparation of semisolid framework of containing glipizide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044]329g of macrogol glyceride stearate and 141g of glyceryl behenate, heat and melt at 80°C, add 5g of glipizide, stir to mix evenly, cool to 60-70°C and fill with capsule liquid Machine filling in No. 1 capsules to make 1000 capsules. In vitro release curve see image 3 shown. (Release 24H)

Embodiment 2

[0046] Glipizide 5, palmitic acid 200g, glyceryl behenate 150g, beeswax 150g, grind until fully dissolved, mix well and heat to 80°C, stir to mix evenly, cool to 60-70°C and use capsule liquid filling machine Fill in No. 1 capsules to obtain 1000 capsules. In vitro release curve see Figure 4 shown. (Release 24H)

Embodiment 3

[0048] 103.4g of macrogol glyceride stearate, 117.5g of carnauba wax, heat and melt at 80°C, add 5g of glipizide, 4.7g of ethyl cellulose (10CP), stir to make the mixture uniform, and slowly add 239.7g of soybean oil, after mixing, was cooled to 60-70°C and filled in No. 1 capsules with a capsule liquid filling machine to obtain 1000 capsules. In vitro release curve see Figure 5 shown. (Release 24H)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A slowly-or controllably-releasing semi-solid medicine for treating diabetes B is proportionally prepared from glipizide and slowly-releasing semi-solid skeleton carrier.

Description

technical field [0001] The invention relates to a sustained and controlled release semi-solid matrix preparation composition containing glipizide. Background technique [0002] Glipizide, white, odorless and tasteless, insoluble in water and ethanol, pKa is 5.9. Its English name is Glipizide, and its chemical name is 1-cyclohexyl-3-{4-[2-(5-methylpyrazine-2-amide)-ethyl]benzenesulfonyl}urea. Its structural formula is as follows: [0003] [0004] Molecular formula: C 21 h 27 N 5 o 4 S, molecular weight: 445.54 [0005] Glipizide is a second-generation sulfonylurea oral hypoglycemic drug, which can promote the secretion of insulin by pancreatic β cells and enhance the effect of insulin on target tissues; it can also stimulate pancreatic α cells to inhibit glucagon secretion. Inhibit liver glycogen breakdown, promote muscle utilization and consumption of glucose. Clinically, it is mainly used for patients with mild to moderate non-insulin-dependent diabetes mellitus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4965
Inventor 顾林金赵晓群沈航孝陆伟根
Owner SHANGHAI INST OF PHARMA IND CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap